Skip to main content
. Author manuscript; available in PMC: 2021 Nov 29.
Published in final edited form as: ACS Chem Neurosci. 2020 Jul 9;11(15):2277–2285. doi: 10.1021/acschemneuro.0c00214

Figure 2.

Figure 2.

Workflow schematic for drug selection. The NIH Clinical Collection was first screened by fluorescence polarization followed by a battery of secondary validation measures including dose–response analysis, specificity counterscreening against PABPN1, and replication through alpha assay orthogonal screening. Compounds passing initial filters were then subjected to a cellular toxicity assay to select potentially translationally relevant candidates.